Implications of protease activation in cardiac dysfunction and development of genetic cardiomyopathy in hamsters.

It has become evident that protein degradation by proteolytic enzymes, known as proteases, is partly responsible for cardiovascular dysfunction in various types of heart disease. Both extracellular and intracellular alterations in proteolytic activities are invariably seen in heart failure associated with hypertrophic cardiomyopathy, dilated cardiomyopathy, hypertensive cardiomyopathy, diabetic cardiomyopathy, and ischemic cardiomyopathy. Genetic cardiomyopathy displayed in different strains of hamsters provides a useful model for studying heart failure due to either cardiac hypertrophy or cardiac dilation. Alterations in the function of several myocardial organelles such as sarcolemma, sarcoplasmic reticulum, myofibrils, mitochondria, as well as extracellular matrix have been shown to be due to subcellular remodeling as a consequence of changes in gene expression and protein content in failing hearts from cardiomyopathic hamsters. In view of the increased activities of various proteases, including calpains and matrix metalloproteinases in the hearts of genetically determined hamsters, it is proposed that the activation of different proteases may also represent an important determinant of subcellular remodeling and cardiac dysfunction associated with genetic cardiomyopathy.

[1]  N. Dhalla,et al.  Role of various proteases in cardiac remodeling and progression of heart failure , 2012, Heart Failure Reviews.

[2]  F. Sellke,et al.  Chymase Inhibition Reduces Infarction and Matrix Metalloproteinase-9 Activation and Attenuates Inflammation and Fibrosis after Acute Myocardial Ischemia/Reperfusion , 2011, Journal of Pharmacology and Experimental Therapeutics.

[3]  J. S. Janicki,et al.  Tryptase/Protease-Activated Receptor 2 Interactions Induce Selective Mitogen-Activated Protein Kinase Signaling and Collagen Synthesis by Cardiac Fibroblasts , 2011, Hypertension.

[4]  H. Granzier,et al.  Titin is a Target of Matrix Metalloproteinase-2: Implications in Myocardial Ischemia/Reperfusion Injury , 2010, Circulation.

[5]  T. Denney,et al.  Chymase Inhibition Prevents Fibronectin and Myofibrillar Loss and Improves Cardiomyocyte Function and LV Torsion Angle in Dogs With Isolated Mitral Regurgitation , 2010, Circulation.

[6]  T. Reinheckel,et al.  Specialized roles for cysteine cathepsins in health and disease. , 2010, The Journal of clinical investigation.

[7]  J. Inserte,et al.  Calpain translocation and activation as pharmacological targets during myocardial ischemia/reperfusion. , 2010, Journal of molecular and cellular cardiology.

[8]  F. Spinale,et al.  Caspase Inhibition Modulates Left Ventricular Remodeling Following Myocardial Infarction Through Cellular and Extracellular Mechanisms , 2010, Journal of cardiovascular pharmacology.

[9]  R. Schulz,et al.  Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. , 2010, Cardiovascular research.

[10]  M. Zile,et al.  Calpain inhibition preserves myocardial structure and function following myocardial infarction. , 2009, American journal of physiology. Heart and circulatory physiology.

[11]  W. Carver,et al.  Cardiac Mast Cells Mediate Left Ventricular Fibrosis in the Hypertensive Rat Heart , 2009, Hypertension.

[12]  M. Crespo,et al.  Early pathophysiological alterations in experimental cardiomyopathy: the Syrian cardiomyopathic hamster. , 2008, Puerto Rico health sciences journal.

[13]  H. Kalbacher,et al.  Cathepsin D: a cellular roadmap. , 2008, Biochemical and biophysical research communications.

[14]  N. Dhalla,et al.  Subcellular remodelling may induce cardiac dysfunction in congestive heart failure. , 2008, Cardiovascular research.

[15]  F. Marín,et al.  Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. , 2008, American heart journal.

[16]  R. Neumar,et al.  Mechanistic Role of Calpains in Postischemic Neurodegeneration , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  S. Nishimura,et al.  Phosphorylation status of regulatory proteins and functional characteristics in myocardium of dilated cardiomyopathy of Syrian hamsters. , 2008, The journal of physiological sciences : JPS.

[18]  Francis G Spinale,et al.  Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. , 2007, Physiological reviews.

[19]  B. Turk,et al.  Protease signalling in cell death: caspases versus cysteine cathepsins , 2007, FEBS letters.

[20]  R. Schulz Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. , 2007, Annual review of pharmacology and toxicology.

[21]  Gang Zhao,et al.  Enhanced myocardial cathepsin B expression in patients with dilated cardiomyopathy , 2006, European journal of heart failure.

[22]  M. Schellings,et al.  Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. , 2006, Cardiovascular research.

[23]  H. Ushikoshi,et al.  Autophagic cardiomyocyte death in cardiomyopathic hamsters and its prevention by granulocyte colony-stimulating factor. , 2006, The American journal of pathology.

[24]  G. Deng,et al.  Serine proteases and cardiac function. , 2005, Biochimica et biophysica acta.

[25]  T. Ebisawa,et al.  A novel scheme of dystrophin disruption for the progression of advanced heart failure. , 2005, Biochimica et biophysica acta.

[26]  D. Szczesna‐Cordary,et al.  Degradation of Myosin Light Chain in Isolated Rat Hearts Subjected to Ischemia-Reperfusion Injury: A New Intracellular Target for Matrix Metalloproteinase-2 , 2005, Circulation.

[27]  N. Dhalla,et al.  Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin–angiotensin system , 2005, Expert review of cardiovascular therapy.

[28]  M. Åbrink,et al.  A Key Role for Mast Cell Chymase in the Activation of Pro-matrix Metalloprotease-9 and Pro-matrix Metalloprotease-2* , 2005, Journal of Biological Chemistry.

[29]  Y. Ishikawa,et al.  Serial Alterations of β-Adrenergic Signaling in Dilated Cardiomyopathic Hamsters , 2004 .

[30]  N. Dhalla,et al.  Role of proteases in the pathophysiology of cardiac disease , 2004, Molecular and Cellular Biochemistry.

[31]  F. Martinon,et al.  Inflammatory Caspases Linking an Intracellular Innate Immune System to Autoinflammatory Diseases , 2004, Cell.

[32]  S. Takai,et al.  An Antiarrhythmic Effect of a Chymase Inhibitor after Myocardial Infarction , 2004, Journal of Pharmacology and Experimental Therapeutics.

[33]  S. Doggrell,et al.  Vascular chymase: pathophysiological role and therapeutic potential of inhibition. , 2004, Cardiovascular research.

[34]  S. Homma,et al.  Simvastatin Preserves Cardiac Function in Genetically Determined Cardiomyopathy , 2004, Journal of cardiovascular pharmacology.

[35]  S. Chakraborti,et al.  Regulation of matrix metalloproteinases: An overview , 2003, Molecular and Cellular Biochemistry.

[36]  S. Chakraborti,et al.  Structure and evolutionary aspects of matrix metalloproteinases: A brief overview , 2003, Molecular and Cellular Biochemistry.

[37]  P. di Nardo,et al.  Identification of a new missense mutation in the mtDNA of hereditary hypertrophic, but not dilated cardiomyopathic hamsters , 2003, Molecular and Cellular Biochemistry.

[38]  D. Kosior,et al.  Tryptase levels in patients after acute coronary syndromes: The potential new marker of an unstable plaque? , 2003, Clinical cardiology.

[39]  P. Kovanen,et al.  Role for chymase in heart failure: angiotensin II-dependent or -independent mechanisms? , 2003, Circulation.

[40]  G. Lip,et al.  Is Thrombogenesis in Atrial Fibrillation Related to Matrix Metalloproteinase-1 and Its Inhibitor, TIMP-1? , 2003, Stroke.

[41]  S. Takai,et al.  Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. , 2003, Cardiovascular research.

[42]  G. Salvesen,et al.  Caspases: keys in the ignition of cell death. , 2002, Chemical reviews.

[43]  Li-qun Jiang,et al.  Transgenic study of the function of chymase in heart remodeling , 2002, Journal of hypertension.

[44]  G. Caughey New developments in the genetics and activation of mast cell proteases. , 2002, Molecular immunology.

[45]  S. Takai,et al.  Beneficial effects of cardiac chymase inhibition during the acute phase of myocardial infarction. , 2002, Life sciences.

[46]  K. Wang,et al.  The calpain family and human disease. , 2001, Trends in molecular medicine.

[47]  T. Ley,et al.  Dipeptidyl Peptidase I Is Essential for Activation of Mast Cell Chymases, but Not Tryptases, in Mice* , 2001, The Journal of Biological Chemistry.

[48]  F. Spinale,et al.  Myocardial remodelling and matrix metallotxoteinases in heart failure: turmoil within the interstitium , 2001, Annals of medicine.

[49]  F. Spinale,et al.  A Matrix Metalloproteinase Induction/Activation System Exists in the Human Left Ventricular Myocardium and Is Upregulated in Heart Failure , 2000, Circulation.

[50]  N. Dhalla,et al.  Changes in the expression of cardiac Na+-K+ ATPase subunits in the UM-X7.1 cardiomyopathic hamster. , 2000, Life sciences.

[51]  H. Urata Pathological involvement of chymase-dependent angiotensin II formation in the development of cardiovascular disease , 2000, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[52]  N. Dhalla,et al.  Role of oxidative stress in cardiovascular diseases , 2000, Journal of hypertension.

[53]  M. Martone,et al.  Altered membrane proteins and permeability correlate with cardiac dysfunction in cardiomyopathic hamsters. , 2000, American journal of physiology. Heart and circulatory physiology.

[54]  S. Takai,et al.  Characterization of recombinant human chymase expressed in Escherichia coli. , 2000, Japanese journal of pharmacology.

[55]  S. Miyamoto,et al.  Extracellular matrix regulation in the development of Syrian cardiomyopathic Bio 14.6 and Bio 53.58 hamsters. , 1999, Journal of molecular and cellular cardiology.

[56]  W. D. De Mello,et al.  Correlation between changes in morphology, electrical properties, and angiotensin-converting enzyme activity in the failing heart. , 1999, European journal of pharmacology.

[57]  G. Schneider,et al.  Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. , 1999, Science.

[58]  G. Angelini,et al.  Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[59]  J C Reed,et al.  Mitochondria and apoptosis. , 1998, Science.

[60]  F. Spinale,et al.  Increased Matrix Metalloproteinase Activity and Selective Upregulation in LV Myocardium From Patients With End-Stage Dilated Cardiomyopathy , 1998 .

[61]  F. Paganelli,et al.  Immunological Identification of Na,K‐ATPase Isoforms in Nonfailing and Failing Myocardium a , 1997, Annals of the New York Academy of Sciences.

[62]  I. Dixon,et al.  Cardiac collagen remodeling in the cardiomyopathic Syrian hamster and the effect of losartan. , 1997, Journal of molecular and cellular cardiology.

[63]  S. Takai,et al.  Chymase is activated in the hamster heart following ventricular fibrosis during the chronic stage of hypertension , 1997, FEBS letters.

[64]  A. Fukamizu,et al.  Activation of angiotensin II‐forming chymase in the cardiomyopathic hamster heart , 1997, Journal of hypertension.

[65]  D. Turk,et al.  Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. , 1997, Biological chemistry.

[66]  S. Kumar,et al.  Differential gene expression of extracellular matrix components in dilated cardiomyopathy , 1996, Journal of cellular biochemistry.

[67]  S. Tyagi,et al.  Role of extracellular matrix metalloproteinases in cardiac remodelling , 1996, Heart Failure Reviews.

[68]  S. Takai,et al.  Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. , 1996, Life sciences.

[69]  A. Walls,et al.  Regulation of the activity of human chymase during storage and release from mast cells: the contributions of inorganic cations, pH, heparin and histamine. , 1995, Biochimica et biophysica acta.

[70]  T. Ogihara,et al.  Chronic administration of angiotensin II receptor antagonist, TCV-116, in cardiomyopathic hamsters. , 1994, The American journal of physiology.

[71]  A. Kobayashi,et al.  Possible involvement of free radicals and antioxidants in the early stages of the development of cardiomyopathy in BIO 14.6 Syrian Hamster. , 1991, Japanese heart journal.

[72]  K. Weber,et al.  Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.

[73]  L. Matrisian,et al.  Mutational analysis of the transin (rat stromelysin) autoinhibitor region demonstrates a role for residues surrounding the "cysteine switch". , 1991, The Journal of biological chemistry.

[74]  K. Misono,et al.  Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. , 1990, The Journal of biological chemistry.

[75]  J. Scheuer,et al.  Troponin-tropomyosin abnormalities in hamster cardiomyopathy. , 1990, The Journal of clinical investigation.

[76]  B. Healy,et al.  Angiotensin II-forming pathways in normal and failing human hearts. , 1990, Circulation research.

[77]  K. Suzuki,et al.  Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. , 1989, The Journal of clinical investigation.

[78]  S. Snyder,et al.  Alterations in Calcium Antagonist Receptors and Sodium-Calcium Exchange in Cardiomyopathic Hamster Tissues , 1989, Circulation research.

[79]  S. Factor,et al.  Intrinsic connective tissue abnormalities in the heart muscle of cardiomyopathic Syrian hamsters. , 1987, The American journal of pathology.

[80]  N. Dhalla,et al.  Sarcolemmal Na+-Ca2+ exchange during the development of genetically determined cardiomyopathy. , 1985, Biochemical and biophysical research communications.

[81]  L. Schwartz,et al.  The fibrinogenolytic activity of purified tryptase from human lung mast cells. , 1985, Journal of immunology.

[82]  N. Dhalla,et al.  Sarcolemmal alterations during the development of genetically determined cardiomyopathy. , 1984, Cardiovascular research.

[83]  E. Sonnenblick,et al.  HEREDITARY AND ACQUIRED CARDIOMYOPATHIES IN EXPERIMENTAL ANIMALS: MECHANICAL, BIOCHEMICAL, AND STRUCTURAL FEATURES * , 1979, Annals of the New York Academy of Sciences.

[84]  E. Sonnenblick,et al.  Depressed myosin ATPase activity in hearts of myopathic hamsters: dissociation from neutral protease activity. , 1978, Journal of molecular and cellular cardiology.

[85]  J. Dingle,et al.  Altered distribution of lysosomal cathepsin D in ischemic myocardium. , 1977, The Journal of clinical investigation.

[86]  M. Peach Renin-angiotensin system: biochemistry and mechanisms of action. , 1977, Physiological reviews.

[87]  N. Dhalla,et al.  Comparison of heart sarcolemmal enzyme activities in normal and cardiomyopathic (UM-X7.1) hamsters. , 1976, Clinical science and molecular medicine.

[88]  R. Schulz,et al.  Activation of MMP-2 as a key event in oxidative stress injury to the heart. , 2009, Frontiers in bioscience.

[89]  N. Zidar,et al.  Caspases in myocardial infarction. , 2007, Advances in clinical chemistry.

[90]  M. Crespo,et al.  Angiotensin II-dependent vascular alterations in young cardiomyopathic hamsters: role for oxidative stress. , 2006, Vascular pharmacology.